X

AggregoTV - DLBCL

AggregoTV - DLBCL

Outcomes of CAR-T Therapy in Patients With Refractory B-Cell Lymphoma

Dr Bruce Levine reports on the outcomes for refractory B-cell Lymphoma patients with CAR T-cell therapy.

04/23/2021
Is Mosunetuzumab Safe and Effective for Elderly Patients With Untreated DLBCL?

Dr Olszewski reports the results of a phase I/II clinical trial of mosunetuzumab as a first-line treatment for elderly and unfit patients with diffuse large B-cell lymphoma.

12/17/2020
Ibrutinib Therapy Prior to Tisa-Cel in R/R DLBCL

Dr Frederick Locke discusses the results of a Phase Ib safety trial of tisagenlecleucel in combination with ibrutinib, a BTK inhibitor, in R/R diffuse large B-cell lymphoma patients.

12/16/2020

Changes in the Classification of DLBCL

Dr Andrew Davies discusses heterogeneity within diffuse large B-cell lymphoma and how molecular profiling of tumor clones can allow reclassification of the disease.

06/22/2020
Alexander Study: CD19/22 Dual Targeting CAR T-Cell Therapy With Pembrolizumab in R/R DLBCL

During the ASCO Annual Meeting, the Lymphoma Hub speaks to Dr Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

06/02/2020
CAR-T Moving Forwards for R/R DLBCL

Dr Anna Sureda gives an overview of first line therapies and the role of stem cell transplantation and CAR-T therapy in the treatment of DLBCL.

03/22/2021
New Models for NHL Care: Innovative Therapy in FL and DLBCL

Dr Nathan H. Fowler, Dr Martin Dreyling, Dr Caron Jacobson and Dr Krish Patel discuss non-Hodgkin lymphoma in this CME activity titled Building New Management Models for NHL Care...

03/04/2021
New Options When DLBCL Doesn’t Respond to Treatment

Linda Bohannon interviews Dr Kami Maddocks about the newest treatments for relapsed/refractory DLBCL.

02/23/2021
Mosunetuzumab for Chemotherapy-Intolerant DLBCL

Dr Adam Olszewski shares the preliminary results of the ongoing Phase I/II trial assessing the safety and efficacy of mosunetuzumab in patients with DLBCL who are intolerant to chemotherapy.

12/14/2020
ZUMA-9: Expanded Access Protocol and OOS Axicabtagene Ciloleucel in R/R DLBCL

Dr Frederick Locke outlines the results of the ZUMA-9 trial of out-of-specification or expanded access to axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B-cell lymphoma patients.

12/06/2020
Real-World Efficacy & Safety Data: CAR-T in DLBCL

Dr Matthew Frigault comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory DLBCL including results from ZUMA-1, JULIET, and TRANSCEND studies.

08/30/2020
Current Treatment Landscape of DLBCL

Dr Edmund Waller explores the current treatment landscape of DLBCL and discusses future approaches being developed, including earlier infusion of CAR T-cell therapies as evaluated in various studies.

08/30/2020
Bi-Specific Antibody - DLBCL and Follicular Lymphoma

Dr Joshua Brody discusses updates from ASH, highlighting DLBCL treatment. 

05/11/2020
Looking Beyond R-CHOP in Diffuse B-Cell Lymphoma

Dr Farzanna Haffizulla interviews Dr Brad Kahl on looking beyond R-CHOP in diffuse b-cell lymphoma.

01/05/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39